ASCO 2014: Doubling Down on Next-Gen Cancer Drugs

What's better than a cancer treatment that binds specifically to its target? A therapy that specifically binds to two targets, of course.

Jun 2, 2014 at 2:30PM

While much of the focus at this year's American Society of Clinical Oncologists meeting will be focused on immuno-oncology partnerships between the so called "checkpoint inhibitors" and targeted cancer therapies, several companies are taking the next step. Amgen (NASDAQ:AMGN)has plans to present data from its unique bispecific antibody blinatumomab at ASCO, and AstraZeneca (NYSE:AZN)and Roche (NASDAQOTH:RHHBY) are among other companies with bispecifics in the works.

What good is a bispecific antibody?
Immuno-oncology has been approached from two different angles. First, there's the cancer vaccine. In order to harness the power of the immune system to fight cancer cells, T-cells must recognize a tumor as being foreign. Cancer vaccines train the immune system to identify markers on the surface of tumor cells, to encourage the body's natural defenses to gobble them up. Cancer vaccines have been notoriously difficult to develop and the only FDA approved vaccine, Provenge from Dendreon, has had little commercial success.

Then there's the checkpoint inhibitors. Checkpoint inhibitors, like the PD-1 inhibitors taking the industry by storm, act by removing built-in brakes on the immune system to boost the response to tumor cells. So far Bristol-Myers Squibb's nivolumab and Merck's MK3475 stand out as the leaders in the group.

By linking antibody fragments that recognize tumor antigens and a T-cell surface marker, it may be possible to harness the benefits of both approaches into a single multi-purpose molecule. That molecule would ideally activate a killer T-cell, and in the process recruit that activated cell to the tumor with its cancer-specific portion.

Who are the players?
When Amgen acquired Micromet in 2012, it picked up a BiTE, or bispecific T-cell engager with potential in fighting B-cell lymphomas and leukemias. Blinatumomab combines features of both cancer vaccines and checkpoint inhibitors by linking antibodies against the CD19 marker for B-cells with antibodies against the T-cell activator CD3. On Tuesday Amgen will present data from a pivotal Phase 2 study of blinatumomab in relapsed/refractory B-precursor acute lymphoblastic leukemia, or ALL, in which B-cells of the immune system have grown rampant.

Blinatumomab, which has received orphan drug designation from the FDA, showed a 43% complete response rate in the confirmatory open label study. According to the American Cancer Society, nearly half of the 80% of patients that achieve remission have a relapse, so a large unmet medical need exists for patients facing the disease for a second time. But while the bispecific immunotherapy appears to be an emerging option for ALL patients, it isn't alone. Ibrutinib, marketed as Imbruvika by Pharmacyclics and Johnson & Johnson, is also in a phase 2 trial to treat ALL.

AstraZeneca and Roche's Genentech have also joined the bispecific antibody party, having both struck deals with privately owned Immunocore for its CD3 ImmTAC bispecific antibodies. The two companies find themselves grabbing more of the immuno-oncology spotlight with impressive data at ASCO, and would do well to channel that momentum into Immunocore's innovative approach. AstraZeneca, having successfully rebuffed takeover bids by Pfizer, must now prove to investors that its worthy of operating as an independent Big Pharma player. That will mean circling the wagons around its until recently under-appreciated oncology pipeline.

For Roche the focus for now is on its checkpoint inhibitor MPDL3280A, and on leveraging its massive pipeline to quietly initiate combination studies with its own targeted drugs. Genentech's respected history of innovation, combined with Immunocore's technology, could provide drug candidates to fill the back end of the pipeline as more mature therapies advance through trials.

The bottom line
It's never too early to ask where the next spark of innovation will come from. With the success of checkpoint inhibitors thus far, and just a touch of innovation, it's possible that bispecific antibodies could solve the problem that cancer vaccines have yet to effectively address. Keep an eye on these players and others as bispecific antibodies gain more traction.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Seth Robey owns shares of Amgen. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers